Your browser doesn't support javascript.
loading
Influence of sub-chronic selective 11ß-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Hamilton, Bradford S; Schoelch, Corinna; Schuler-Metz, Annette; Krosky, Paula; Lala, Deepak S; Claremon, David A; McGeehan, Gerard M.
Afiliación
  • Hamilton BS; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstraße 67, 88397 Biberach an der Riß, Germany. Electronic address: bradford.hamilton@boehringer-ingelheim.com.
  • Schoelch C; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstraße 67, 88397 Biberach an der Riß, Germany.
  • Schuler-Metz A; Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorferstraße 67, 88397 Biberach an der Riß, Germany.
  • Krosky P; Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, United States.
  • Lala DS; Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, United States.
  • Claremon DA; Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, United States.
  • McGeehan GM; Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, United States.
Eur J Pharmacol ; 789: 68-74, 2016 Oct 15.
Article en En | MEDLINE | ID: mdl-27393460
Inhibition of local cortisol regeneration from circulating cortisone by blocking 11ß-hydroxysteroid dehydrogenase 1 (11ß-HSD1) has been shown to ameliorate the risk factors associated with the metabolic syndrome. Chronic modulation of glucocorticoid homeostasis may result in hypothalamic-pituitary-adrenal (HPA) axis stimulation. HPA axis over-activation leading androgen excess would be undesirable in a therapeutic intervention designed to treat a chronic condition such as the metabolic syndrome. To address whether 11ß-HSD1 inhibition would lead to excess androgens, we treated female cynomolgus monkeys with a selective inhibitor, BI 135558, for 4 weeks. Continual action of the compound over the dosing period was confirmed by constant plasma exposure, and a maintained change in urinary glucocorticoid metabolites consistent with 11ß-HSD1 inhibition. No significant changes in adrenal function, as evidenced by an adrenocorticotropic hormone (ATCH) challenge, were observed. An examination of androgenic hormones revealed a slight increase in dehydroepiandrosterone sulfate (DHEA-S), while other hormones such as testosterone remained within reference values. Overall, treatment with BI 135558 in monkeys did not result in obvious over-activation of the HPA axis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazinas / Sistema Hipófiso-Suprarrenal / Piridonas / 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1 / Inhibidores Enzimáticos / Sistema Hipotálamo-Hipofisario Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Eur J Pharmacol Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazinas / Sistema Hipófiso-Suprarrenal / Piridonas / 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1 / Inhibidores Enzimáticos / Sistema Hipotálamo-Hipofisario Tipo de estudio: Risk_factors_studies Límite: Animals Idioma: En Revista: Eur J Pharmacol Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos